Research Article
Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients
Table 1
Demographic and clinical characteristics between PD-NC, PD-MCI, and PDD groups.
| | PD-NC | PD-MCI | PDD | |
| N | 37 | 44 | 11 | — | Age | 68.08 ± 6.202 | 69.82 ± 6.366 | 71.27 ± 4.563 | 0.237a | Male (%) | 25 (67.6%) | 34 (77.3%) | 7 (63.6%) | 0.511b | Education (year) | 12.35 ± 2.879 | 11.63 ± 3.441 | 10.73 ± 2.284 | 0.225c | Disease duration (year) | 5.32 ± 5.716 | 5.18 ± 3.598 | 7.82 ± 3.401 | 0.033c | H–Y staging | 1.70 ± 0.6714 | 1.90 ± 0.6522 | 2.45 ± 0.650 | 0.009c | Smoke (−) | 34 (91.9%) | 38 (86.4%) | 10 (90.9%) | 0.712b | Alcohol (−) | 34 (91.9%) | 39 (88.6%) | 9 (81.8%) | 0.656b | Diabetes (−) | 32 (86.5%) | 39 (88.6%) | 9 (81.8%) | 0.838b | Hypertension (−) | 27 (73.0%) | 29 (65.9%) | 7 (63.6%) | 0.739b | Coronary heart disease (−) | 31 (83.8%) | 36 (81.8%) | 11 (100%) | 0.139b | Cerebrovascular disease (−) | 33 (89.2%) | 39 (88.6%) | 10 (90.0%) | 0.976b | Levodopa (+) | 25 (67.6%) | 36% (81.8%) | 10 (90.0%) | 0.151b | Dopamine agonists (+) | 22 (59.5%) | 20 (45.5%) | 5 (45.5%) | 0.418b | COMT inhibitor (+) | 3 (8.1%) | 10 (22.7%) | 0 (0%) | 0.061b | MAO-B inhibitor (+) | 13 (35.1%) | 8 (18.2%) | 1 (9.1%) | 0.090b | Anticholinergic (+) | 0 (0%) | 2 (4.5%) | 1 (9.1%) | 0.177b | Amantadine (+) | 3 (8.1%) | 7 (15.9%) | 2 (18.2%) | 0.488b | LEDD (mg/d) | 323.97 ± 249.571 | 430.73 ± 287.325 | 540.91 ± 301.719 | 0.038a | UPDRS-III | 12.89 ± 8.906 | 20.48 ± 13.473 | 26.00 ± 11.773 | 0.001c | BDI | 5.68 ± 4.295 | 11.45 ± 8.019 | 16.45 ± 10.727 | <0.001c | MDRS | 138.16 ± 6.265 | 131.43 ± 9.260 | 114.27 ± 15.755 | <0.001c |
|
|
aOne-way analysis of variance (ANOVA); bChi-square test; cKruskal–Wallis test. PD: Parkinson’s disease; PD-NC: PD patients with normal cognition; PD-MCI: PD patients with mild cognitive impairment; PDD: PD patients with dementia; H–Y staging: Hoehn and Yahr staging; COMT inhibitor: catechol O-methyltransferase inhibitor; MAO-B inhibitor: monoamine oxidase-B inhibitor; LEDD: levodopa equivalent daily dose; UPDRS-III: the Unified Parkinson’s Disease Rating Scale part III; BDI: Beck Depression Inventory; MDRS: Mattis Dementia Rating Scale.
|